10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
Rhea-AI Summary
10x Genomics (Nasdaq: TXG) reported preliminary, unaudited select results for Q4 and full-year 2025. Q4 revenue was approximately $166.0M (up 11% sequential, +1% YoY). FY2025 revenue was approximately $642.8M, or $598.7M excluding $44.1M of patent litigation settlement payments, a 2% decrease year‑over‑year on the adjusted basis. Instruments revenue fell sharply (FY instruments ~$56.8M, -39% YoY). Consumables grew to ~$507.2M for the year (+3% YoY). Cash and marketable securities were about $520M at year end. Company will present at the J.P. Morgan Healthcare Conference on Jan 12, 2026.
Positive
- FY2025 consumables revenue +3% to $507.2M
- Q4 2025 revenue $166.0M, up 11% sequential
- Spatial consumables FY growth +19% to $144.0M
- Cash and marketable securities ≈ $520M at Dec 31, 2025
- Cumulative Chromium instruments >6,400; Spatial instruments >1,500
Negative
- FY2025 instruments revenue down 39% to $56.8M
- FY Single Cell instruments revenue down 36% to $22.7M
- FY Spatial instruments revenue down 41% to $34.1M
- Adjusted FY2025 revenue (excl. $44.1M settlements) declined 2% YoY
Key Figures
Market Reality Check
Peers on Argus
Pre-news, TXG was up 6.07% while peers were mixed: CERT -4.31%, SDGR -2.34%, OMCL +1.06%, PHR +0.47%, GDRX +0.72%, suggesting stock-specific strength rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 29 | Conference participation | Neutral | +0.9% | Announced upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 18 | Partnership/consortium | Positive | -0.9% | Launched ASTRA consortium to build pan-cancer spatial atlas using Xenium platform. |
| Nov 11 | Conference participation | Neutral | +0.6% | Management participation in Wolfe Research Healthcare Conference fireside chat. |
| Nov 06 | Quarterly earnings | Neutral | -3.6% | Reported Q3 2025 results with $149.0M revenue and narrower operating and net losses. |
| Oct 29 | Product launch | Positive | -3.3% | Introduced next-gen Chromium Flex assay to scale single cell research throughput. |
Recent news flow shows positive product or partnership announcements sometimes met with negative price reactions, while conference appearances tend to see mild positive moves. Earnings events in 2025 often coincided with modestly negative next-day performance.
Over the last six months, 10x Genomics reported multiple product and financial updates. Q3 2025 results showed revenue of $149.0M with narrower losses and cash of $482.1M. Earlier in 2025, the company launched its next-generation Chromium Flex assay and helped form the ASTRA spatial cancer consortium. Management also highlighted conference participation, including the 44th Annual J.P. Morgan Healthcare Conference. Against this backdrop, today’s preliminary 2025 figures add early detail on revenue mix, consumables growth, and balance sheet strength.
Market Pulse Summary
This announcement provides preliminary detail on 10x Genomics’ Q4 and full-year 2025 performance, highlighting Q4 revenue of $166.0M, FY 2025 revenue excluding settlements of $598.7M, and cash and marketable securities of about $520M. It also underscores the installed base of more than 6,400 Chromium and 1,500 Spatial instruments. Investors may watch how final audited numbers compare with these estimates and how the balance between instruments and consumables evolves in 2026.
Key Terms
patent litigation settlements regulatory
marketable securities financial
AI-generated analysis. Not financial advice.
Preliminary, Unaudited Select Fourth Quarter 2025 Financial Results
- Revenue of approximately
$166.0 million 11% growth sequentially and1% growth compared to the corresponding prior year period. - Instruments revenue of approximately
$15.5 million 29% growth sequentially and a36% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately$6.1 million 24% growth sequentially and a44% decrease year-over-year, and$9.4 million 32% growth sequentially and a30% decrease year-over-year. - Consumables revenue of approximately
$141.7 million 11% growth sequentially and a6% increase as compared to the corresponding prior year period. Consumables revenue consists of approximately$100.8 million 9% growth sequentially and3% growth year-over-year, and$41.0 million 16% growth sequentially and14% growth year-over-year. - Services and License and Royalty revenue of approximately
$8.8 million 3% decrease sequentially and23% growth year-over-year.
Preliminary, Unaudited Select Full Year 2025 Financial Results
- Revenue of approximately
$642.8 million $44.1 million $598.7 million 2% decrease from the prior year. - Instruments revenue of approximately
$56.8 million 39% decrease from the prior year. Instruments revenue consists of approximately$22.7 million 36% decrease year-over-year and$34.1 million 41% decrease year-over-year. - Consumables revenue of approximately
$507.2 million 3% growth over the prior year. Consumables revenue consists of approximately$363.2 million 2% decrease year-over-year and$144.0 million 19% growth year-over-year. - Services and License and Royalty revenue of approximately
$34.8 million $44.1 million 41% growth year-over-year. - Increased cumulative Chromium instruments sold to more than 6,400 instruments and cumulative Spatial instruments sold to more than 1,500 as of the end of 2025.
- Single Cell consumables reactions sold increased by more than
20% compared to the prior year period. - Cash, cash equivalents and marketable securities of approximately
$520 million
"I am incredibly proud of the tenacity and ingenuity our team displayed throughout 2025," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "While the macro environment was challenging, the team forged even stronger partnerships with customers, made important progress across our product roadmap and maintained tight operational discipline, leading to a significant strengthening of our balance sheet. I am confident that our greatest impact lies ahead and 10x is well positioned for the future."
J.P. Morgan Healthcare Conference
10x Genomics, Inc. is providing these updates in advance of its participation in the 44th Annual J.P. Morgan Healthcare Conference, which begins tomorrow. A live webcast of the company's presentation and question and answer session, which begins at 8:15 a.m. Pacific Time on Monday, January 12, 2026, will be available on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.
Preliminary Select Results Subject to Adjustment
10x Genomics, Inc. has not completed preparation of its consolidated financial statements for the fourth quarter or fiscal year of 2025. The select results presented in this news release for the fourth quarter and year ended December 31, 2025 are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete preparation of our consolidated financial statements for the year ended December 31, 2025. 10x Genomics, Inc. is in the process of completing its customary year-end close and review procedures as of and for the fourth quarter and year ended December 31, 2025, and there can be no assurance that final results for these periods will not differ from these estimates. During the course of the preparation of 10x Genomics, Inc.'s consolidated financial statements and related notes as of and for the year ended December 31, 2025, we or our independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary unaudited financial estimates presented herein.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expected financial results for the fourth quarter and year ended December 31, 2025 and our future opportunities and performance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information available to management as of the date hereof. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results reflected in the forward-looking statements will be achieved or will occur. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K, 10-Q and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. 10x Genomics' products are for research use only (RUO) and are not for use in diagnostic procedures. "10x Genomics", "Chromium" and "Xenium" are trademarks of 10x. 10x trademarks are the sole property of 10x, and are subject to legal protection in
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-announces-preliminary-select-fourth-quarter-and-full-year-2025-results-302657895.html
SOURCE 10x Genomics, Inc.
FAQ
What was 10x Genomics (TXG) preliminary revenue for Q4 2025?
How did 10x Genomics' full-year 2025 revenue compare excluding settlements (TXG)?
What happened to 10x Genomics instruments revenue in 2025 (TXG)?
Did 10x Genomics' consumables sales grow in 2025 (TXG)?
How strong is 10x Genomics' cash position at year end (TXG)?
When will 10x Genomics present at the J.P. Morgan Healthcare Conference (TXG)?
